Search results for "PROGRESS"

showing 10 items of 1620 documents

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting

2020

Background Machine learning algorithms using magnetic resonance imaging (MRI) data can accurately discriminate parkinsonian syndromes. Validation in patients recruited in routine clinical practice is missing. Objective The aim of this study was to assess the accuracy of a machine learning algorithm trained on a research cohort and tested on an independent clinical replication cohort for the categorization of parkinsonian syndromes. Methods Three hundred twenty-two subjects, including 94 healthy control subjects, 119 patients with Parkinson's disease (PD), 51 patients with progressive supranuclear palsy (PSP) with Richardson's syndrome, 35 with multiple system atrophy (MSA) of the parkinsoni…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseParkinson's diseasemultiple system atrophyProgressive supranuclear palsyDiagnosis Differential03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationParkinsonian DisordersmedicineHumansmultimodal magnetic resonance imagingReceiver operating characteristicmedicine.diagnostic_testbusiness.industryParkinsonismMagnetic resonance imagingprogressive supranuclear palsymedicine.diseaseMagnetic Resonance Imaging3. Good healthnervous system diseasesmachine learning algorithm030104 developmental biologyDiffusion Tensor ImagingNeurologyCategorizationnervous systemCohort[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurology (clinical)Supranuclear Palsy Progressivebusiness030217 neurology & neurosurgeryDiffusion MRI
researchProduct

The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and a…

2021

  The proteasome to immunoproteasome (iPS) switch consists of β1, β2 and β5 subunit replacement by low molecular weight protein 2 (LMP2), LMP7 and multicatalytic endopeptidase-like complex-1 (MECL1) subunits, resulting in a more efficient peptide preparation for major histocompatibility complex 1 (MHC-I) presentation. It is activated by toll-like receptor (TLR) agonists and interferons and may also be influenced by genetic variation. In a previous study we found an iPS upregulation in peripheral cells of patients with immunoglobulin A nephropathy (IgAN). We aimed to investigate in 157 IgAN patients enrolled through the multinational Validation Study of the Oxford Classification of IgAN (VAL…

0301 basic medicinemedicine.medical_specialtyProteasome Endopeptidase Complex030232 urology & nephrologyCD46; IgA nephropathy; biomarkers; complement; immune proteasome; progression; risk factorsMajor histocompatibility complexMembrane Cofactor Protein03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicinerisk factorsHumanscomplementRNA MessengerReceptorCD46Transplantationmedicine.diagnostic_testbiologybusiness.industrybiomarkersPSMB8Glomerulonephritis IGAIgA nephropathyPSMB9medicine.diseaseUp-RegulationTLR2030104 developmental biologyEndocrinologyNephrologybiology.proteinprogressionRenal biopsyimmune proteasomebusinessKidney diseaseGenome-Wide Association StudyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Dietary restriction: could it be considered as speed bump on tumor progression road?

2016

Dietary restrictions, including fasting (or long-term starvation), calorie restriction (CR), and short-term starvation (STS), are considered a strong rationale that may protect against various diseases, including age-related diseases and cancer. Among dietary approaches, STS, in which food is not consumed during designed fasting periods but is typically not restricted during designated feeding periods, seems to be more suitable, because other dietary regimens involving prolonged fasting periods could worsen the health conditions of cancer patients, being they already naturally prone to weight loss. Until now, the limited amount of available data does not point to a single gene, pathway, or …

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaCalorie restrictionCancer cellBiologyBioinformaticsCellular stress response03 medical and health sciencesWeight lossNeoplasmsCellular stress responseInternal medicinemedicineAnimalsHumansChemotherapyShort-term starvationSettore MED/49 - Scienze Tecniche Dietetiche ApplicateCaloric RestrictionStarvationCancerCancer cells; Cellular stress response; Chemotherapy; Diet; Fasting; Short-term starvationFastingGeneral Medicinemedicine.diseaseDietSettore MED/18 - Chirurgia Generale030104 developmental biologyEndocrinologyTumor progressionCancer cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioSignal transductionmedicine.symptomTumor Biology
researchProduct

When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

2021

While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With …

0301 basic medicinemedicine.medical_specialtyad spectrumGradual progressionVariable timeInfluential PublicationsReviewDiseaseCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAlzheimer DiseaseRisk FactorsmedicineHumansDementiaPhysical and Theoretical ChemistryIntensive care medicineCognitive impairmentlcsh:QH301-705.5Molecular BiologyPathologicalad dynamicimaging biomarkersSpectroscopyCerebral atrophybusiness.industryOrganic ChemistrybiomarkerscsfGeneral Medicinemedicine.diseaseComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999business030217 neurology & neurosurgerydementiaInternational Journal of Molecular Sciences
researchProduct

Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

2019

Abstract Background ABBV-181 is a humanized anti-PD1 monoclonal antibody; dose finding and early safety, PK and pharmacodynamic data have been reported (ESMO18). This report summarizes data from the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts in the Ph1 FIH study (NCT03000257). Methods Patients (pts) with previously treated, advanced HNSCC and NSCLC received ABBV-181 IV, 250 mg Q2W or 500 mg Q4W to progression. Response was assessed by RECIST v1.1 and iRECIST. Results As of April 2019, 81 pts were dosed. Table . 1288P n (%) HNSCC n = 41 NSCLC n = 40 Median days on treatment, range 72, 1–407 71, 1–421 Dose: 250 mg/500 mg 31/10 19/21 …

0301 basic medicinemedicine.medical_specialtybusiness.industryAnti pd 1Physical healthStock optionsHematology03 medical and health sciencesNeoplasm progressionDose finding030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinePartial responseMedicinemedicine.symptombusinessHead and neck carcinomaConfusionAnnals of Oncology
researchProduct

Update and guidance on management of myopia : European Society of Ophthalmology in cooperation with International Myopia Institute

2021

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, t…

0301 basic medicinemedicine.medical_specialtygenetic structuresmedicine.medical_treatmentatropinePsychological interventionReviewsorthokeratologylikinäköisyyspreventive medicineehkäisevä lääketiede03 medical and health sciences0302 clinical medicineOphthalmologynäkövammatEpidemiologyMyopiaPrevalenceMedicineHumansmyopiaPreventive healthcareBlindnessbusiness.industrypathologic myopiaPathological myopiaOrthokeratologyHigh myopiaTreatment optionsGeneral Medicinemedicine.diseasetime spent outdoorsmyopia reduction interventionsMyopia Degenerative/epidemiologyeye diseasesOphthalmology030104 developmental biologyMyopia Degenerativesilmätaudit030221 ophthalmology & optometryDisease Progressionsense organsbusinessOrthokeratologic Proceduresblindnesssokeus
researchProduct

Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs

2017

Nussbaum et al. found that tumor suppression through innate lymphoid cells (ILCs) cannot be predicted solely based on the ILC phenotype and lineage but that their immune properties are shaped both by their ontogeny and by the tissue microenvironment they reside in.

0301 basic medicinemedicine.medical_treatmentImmunology314610 Medicine & healthBiology10263 Institute of Experimental ImmunologyArticle31103 medical and health sciencesMiceRAR-related orphan receptor gammaCell Line TumormedicineImmunology and AllergyAnimalsLymphocytesskin and connective tissue diseasesTranscription factorResearch ArticlesMice Knockout2403 ImmunologyInnate lymphoid cellNeoplasms ExperimentalNuclear Receptor Subfamily 1 Group F Member 3PhenotypeCell biologybody regionsKiller Cells NaturalMice Inbred C57BL030104 developmental biologyCytokineCellular MicroenvironmentCell cultureTumor progressionInterleukin 122723 Immunology and AllergyCytokines570 Life sciences; biologyTranscription Factors
researchProduct

Insufficient generation of Th17 cells in IL-23p19-deficient BALB/c mice protects against progressive cutaneous leishmaniasis

2017

Healing of leishmaniasis-a parasitic skin disease-is associated with high levels of secreted interferon (IFN)γ and IL-12 in resistant C57BL/6 mice and humans. Susceptible BALB/c mice predominantly react with a Th17/Th2/Treg-related immune response and finally succumb to infection. Previously, we showed that BALB/c IL-17A-/- mice are protected against Leishmania (L.) major infections, indicating that IL-17A-predominantly produced by Th17 cells-plays an important role for disease outcome. We now investigated DC-derived cytokines and finally identified IL-23p19 as key cytokine responsible for induction of Leishmania-specific Th17 cells that play an important role for progressive disease in sus…

0301 basic medicinemedicine.medical_treatmentLeishmaniasis CutaneousDermatologyPolymerase Chain ReactionBiochemistryBALB/cInterferon-gammaMice03 medical and health sciences0302 clinical medicineImmune systemCutaneous leishmaniasisInterferonInterleukin 23AnimalsMedicineMolecular BiologyLeishmania majorMice Inbred BALB Cbiologybusiness.industryLeishmaniasisDendritic CellsLeishmaniabiology.organism_classificationmedicine.disease030104 developmental biologyCytokineImmunologyDisease ProgressionInterleukin-23 Subunit p19CytokinesTh17 Cellsbusiness030215 immunologymedicine.drugExperimental Dermatology
researchProduct